Literature DB >> 8019093

Outcome of pregnancies inadvertently exposed to gonadotropin-releasing hormone analogues (GnRH-a) in early gestation.

Y Gonen1, M Dirnfeld, H Abramovici.   

Abstract

In recent years the down-regulation of pituitary function by GnRH-a, before and during ovarian stimulation for IVF, has been widely used. When GnRH-a are commenced in the luteal phase, it is inevitable that some early human embryos will be exposed. To the best of our knowledge the total number of reported deliveries following exposure is less than 30. We report here a further nine uneventful pregnancies with successful neonatal outcomes and three early miscarriages. It is our belief that the favorable outcome in patients presented here, who inadvertently received GnRH-a in early unsuspected gestation, is related to the use of short-acting analogues (Buserelin nasal spray). This enabled immediate discontinuation of the drug when the presence of pregnancy was suspected. In addition, the routine administration of progesterone supplements is strongly recommended, regardless of the hormonal levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8019093     DOI: 10.1007/bf01228095

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  14 in total

1.  Exposure to LHRH agonists in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation.

Authors:  A E Jackson; P Curtis; N Amso; R W Shaw
Journal:  Hum Reprod       Date:  1992-10       Impact factor: 6.918

2.  Ectopic pregnancy after luteal phase initiation of gonadotropin-releasing hormone analog before in vitro fertilization.

Authors:  R Forman; J Robinson; D Egan; C Ross; B Gosden; D Barlow
Journal:  Fertil Steril       Date:  1990-07       Impact factor: 7.329

3.  Pregnancy outcome following early exposure to maternal luteinizing-hormone-releasing hormone agonist (buserelin).

Authors:  D Dicker; J A Goldman; I Vagman; N Eckstein; D Ayalon
Journal:  Hum Reprod       Date:  1989-04       Impact factor: 6.918

4.  Chorionic gonadotropin secretion by human embryos in vitro.

Authors:  D L Hay; A Lopata
Journal:  J Clin Endocrinol Metab       Date:  1988-12       Impact factor: 5.958

5.  Pregnancy: a risk to initiation of leuprolide acetate during the luteal phase before controlled ovarian hyperstimulation.

Authors:  P Serafini; J Batzofin; J Kerin; R Marrs
Journal:  Fertil Steril       Date:  1988-08       Impact factor: 7.329

6.  Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey.

Authors:  H M Fraser; J Sandow
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

7.  Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor.

Authors:  R F Casper; S S Yen
Journal:  Science       Date:  1979-07-27       Impact factor: 47.728

8.  The influence of inadvertent intranasal buserelin administration in early pregnancy.

Authors:  J Smitz; M Camus; P Devroey; N Bollen; H Tournaye; A C Van Steirteghem
Journal:  Hum Reprod       Date:  1991-02       Impact factor: 6.918

9.  Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone.

Authors:  A Herman; R Ron-El; A Golan; H Nachum; Y Soffer; E Caspi
Journal:  Hum Reprod       Date:  1992-04       Impact factor: 6.918

10.  Failure to induce early abortion by huge doses of a superactive LRH agonist in women.

Authors:  G Skarin; S J Nillius; L Wide
Journal:  Contraception       Date:  1982-11       Impact factor: 3.375

View more
  1 in total

Review 1.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.